Pharmacotherapy of age-related macular degeneration

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 17, 2008, Pages 3045-3052

  Ahmadi, M Amir ^a   Lim, Jennifer I ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Age related macular degeneration; Anti VEGF; Combination therapy; Geographic atrophy; Pharmacotherapy; Photodynamic therapy

Indexed keywords

AFLIBERCEPT; AG 013958; ANTIOXIDANT; BEVACIZUMAB; BEVASIRANIB; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; COMPSTATIN; DEXAMETHASONE; DOCOSAHEXANOIC ACID; EPIDERMAL GROWTH FACTOR; HEXANOIC ACID DERIVATIVE; MIDOSTAURIN; OMEGA 3 FATTY ACID; PEGAPTANIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; RUBOXISTAURIN; SEMAXANIB; SIRNA 027; SMALL INTERFERING RNA; SUNITINIB; SYNTHETIC PEPTIDE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALALANIB; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB; VERTEPORFIN;

ADJUVANT THERAPY; ANGIOGENESIS; BINDING AFFINITY; BLOOD VESSEL PERMEABILITY; CAUCASIAN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPLEMENT SYSTEM; CONJUNCTIVAL HEMORRHAGE; DOSAGE SCHEDULE COMPARISON; DRUG ACTIVATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENDOPHTHALMITIS; EUROPEAN AMERICAN; EYE PAIN; GENE EXPRESSION; HAPLOTYPE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOXIA; INCIDENCE; INFLAMMATION; INTRAOCULAR INFLAMMATION; INTRAOCULAR PRESSURE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OPTICAL COHERENCE TOMOGRAPHY; PHOTOACTIVATION; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PROTEINURIA; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; RNA INTERFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; THROMBOEMBOLISM; TISSUE INJURY; TRAUMATIC CATARACT; TREATMENT DURATION; UPREGULATION; VISUAL IMPAIRMENT; VITREOUS FLOATERS;

AGING; ANGIOGENESIS INHIBITORS; ANIMALS; DRUG THERAPY, COMBINATION; HUMANS; MACULAR DEGENERATION; NEOVASCULARIZATION, PATHOLOGIC;

EID: 57549094437     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802473480     Document Type: Review

References (52)

1. Wang JJ, Rochtchina E, Lee AJ, et al. Ten year incidence and progression of age-related maculopathy the Blue Mountains Eye Study. Ophthalmol 2007;114(1):92-8
2. Van Leeuwen R, Klaver CC, Vingerling JR, et al. The risk and natural course of age-related maculopathy follow up at 612 years in the Rotterdam Study. Arch Ophthalmol 2003;121(4):519-26
3. Macular Photocoagulation Study Group: Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1220-31
4. Tap Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. TAP Report 1. Arch Ophthalmol 1999;117:1329-45
5. Augustin AJ, Schmidt-Erfurth U Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;141:638-45
6. Gragoudas ES, Adamis AP, Cunningham JR, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
7. Age-Related Eye Disease Study Research Group: Areds report no. 8. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for advanced age-related macular degeneration and vision loss. Arch Ophthalmol 2001;119:1417-36
8. Chong EW, Wong TY, Kreis AJ, et al. Dietary antioxidants and primary prevention of age related macular degeneration systematic review and meta-analysis. BMJ 2007;335(7623):755
9. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl Acad Sci USA 2005;102(20):7227-32
10. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-9
11. Edwards AO, Ritter III R, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421-4
12. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age related macular degeneration. Science 2005;308:419-21
13. Hageman GS, Hancox LS, Taiber AJ, et al. Amd Clinical Study Group: Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Ann Med 2006;38(8):592-604
14. Janssen BJ, Halff EF, Lambris JD, et al. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J Biol Chem 2007;282(40):29241-247
15. Nilsson B, Larsson R, Hong J, et al. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 1998;92(5):1661-7
16. Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP Report No 2. Arch. Ophthalmol 2001;119:198-207
17. Verteporfin In Photodynamic Therapy Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol 2001;131:541-60
18. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995;1(2):182-93
19. Gottsch JD, Pou S, Bynoe LA, et al. Hematogenous photosensitization. A mechanism for the development of age-related macular degeneration. Invest Ophthalmol Vis Sci 1990;31:1674-82
20. Gragoudas ES, Adamis AP, Cunningham JR, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
21. Gonzales CR. VEGF Inhibition Study In Ocular Neovascularization Clinical Trial Group: Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005;25:815-27
22. Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 2007;85(4):425-30
23. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin N Am 2006;19(3):361-72
24. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year Anchor results. Am J Ophthalmol 2007;144(6):850-7
25. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of Ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145(2):239-48
26. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal Ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143(4):566-83
27. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
28. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-8
29. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90
30. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511
31. Thompson JT, Small interfering RNA (Cand5) for the treatment of subfoveal CNV. In AAO Annual Meeting, 2006
32. Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006;13(3):225-34
33. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008;452(7187):591-7
34. Wen R, Zhao I, Liu Y, et al. VEGF trap induces significant regression of existing choroidal neovascularization (CNV). Invest Ophthalmol Vis Sci 2005;46: E-Abstr. 5307
35. Nguyen QD, Shah SM, Hafiz G, et al. A Phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113(9):1522
36. Nguyen QD. For The Clear-It 1 Investigators: A randomized comparison of the safety, tolerability, and bioactivity study of two dose levels of intravitreal VEGF trap in patients with neovascular age-related macular degeneration. Presented at the Retina Society Annual Scientific Meeting, Boston; 2007
37. Speicher MA, Danis RP, Criswell M, et al. Pharmacologic therapy for diabetic retinopathy. Expert Opin Emerg Drugs 2003;8(1):239-50
38. Takahashi H, Obata R, Tamaki Y. A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo. J Ocul Pharmacol Ther 2006;22(4):213-8
39. Saishin Y, Lima Silva R, Callahan K, et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci 2003;44(11):4989-93
40. Tombran-Tink J, Shivaram SM, Chader GJ, et al. Expression, secretion, and age-related down regulation of pigment epithelium-derived factor, a serpin with neurotrophic activity. J Neurosci 1995;15(7 Part 1):4992-5003
41. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a Phase I clinical trial. Hum Gene Ther 2006;17(2):167-76
42. Perrin RM, Konopatskaya O, Qiu Y, et al. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth fisctor. Diabetologia 2005;48(11):2422-7
43. Lima Silva R, Kachi S, et al. Trans-scleral delivery of polyamine analogs for ocular neovascularization. Exp Eye Res 2006;83(5):1260-7
44. Heeschen C, Weis M, Aicher A, et al. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest 2002;110(4):527-36
45. Easton JB, Houghton PJ Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets 2004;8(6):551-64
46. Dejneka NS, Kuroki AM, Fosnot J, et al. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 2004;10:964-72
47. Schmidt-Erfurth U, Schloetzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3 and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473-80
48. Debefve E, Pegaz B, Van Den Bergh H, et al. Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne (R), in the CAM model. Angiogenesis 2008;11(3):235-43
49. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-46
50. Tatar O, Adam A, Shinoda K, et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol 2006;142:95-104
51. Heier JS, Boyer DS, Ciulla TA, et al. And The Focus Study Group: Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration year 1 results of the focus study. Arch Ophthalmol 2006;124:1532-42
52. Kaiser PK. for the Veritas Study Group. Verteporfin therapy in combination with pegaptanib or triamcinolone for wet AMD. 12-month study results. In AAO Annual Meeting, 2007